Freeform Search

Database: US Pre-Grant Publication Full-Text Database
US Patents Full-Text Database
US OCR Full-Text Database
EPO Abstracts Database
JPO Abstracts Database
Derwent World Patents Index
IBM Technical Disclosure Bulletins

Term: L19 and krieg

Display: 10 **Documents in Display Format:** - **Starting with Number** 1

Generate: ○ **Hit List** ◉ **Hit Count** ○ **Side by Side** ○ **Image**

Search Clear Interrupt

Search History

DATE: Monday, October 18, 2004 Printable Copy Create Case

Set Name side by side	Query	Hit Count	Set Name result set
DB=PGPB,USPT,USOC,EPAB,JPAB,DWPI; PLUR=YES; OP=ADJ			
L20	L19 and krieg	143	L20
L19	L18 and l15	610	L19
L18	l7 and l14	799	L18
L17	L16 same l14	13	L17
L16	L15 with l9	4340	L16
L15	antigen	124937	L15
L14	cpg with oligonucleotide	2011	L14
L13	cpg with oligonucleoitide	0	L13
L12	l9 and l6	53	L12
L11	l9 same l6	12	L11
L10	L9 same l8	4	L10
L9	exposed	1340699	L9
L8	L7 same l6	22	L8
L7	mucosal or intran$	79245	L7
L6	cpg with oligonucleotide with antigen	122	L6
L5	cpg with intranasal	15	L5

L4	cpg with mucosal	47	L4
L3	mucosal and l2	1	L3
L2	6218371.pn.	2	L2
L1	6218791.pn.	2	L1

END OF SEARCH HISTORY

Previous Doc Next Doc Go to Doc#
First Hit Fwd Refs

Generate Collection

L4: Entry 41 of 47 File: USPT Jun 18, 2002

US-PAT-NO: 6406705
DOCUMENT-IDENTIFIER: US 6406705 B1

TITLE: Use of nucleic acids containing unmethylated CpG dinucleotide as an adjuvant

DATE-ISSUED: June 18, 2002

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Davis; Heather L.	Ottawa			CA
Schorr; Joachim	Hilden			DE
Krieg; Arthur M.	Iowa City	IA		

US-CL-CURRENT: 424/278.1; 424/204.1, 424/279.1, 424/282.1, 536/23.72, 930/200, 930/210, 930/220

CLAIMS:

We claim:

1. A composition of a synergistic combination of adjuvants, comprising:

an effective amount for inducing a synergistic adjuvant response of a combination of adjuvants, wherein the combination of adjuvants includes at least one oligonucleotide containing at least one unmethylated CpG dinucleotide and at least one non-nucleic acid adjuvant.

2. The composition of claim 1, wherein the non-nucleic acid is an adjuvant that creates a depo effect.

3. The composition of claim 2, wherein the adjuvant that creates a depo effect is selected from the group consisting of alum, emulsion based formulations, mineral oil, non-mineral oil, water-in-oil emulsions, water-in-oil-in-water emulsions, Seppic ISA series of Montanide adjuvants; MF-59; and PROVAX.

4. The composition of claim 1, wherein the non-nucleic acid adjuvant is an immune stimulating adjuvant.

5. The composition of claim 4, wherein the immune stimulating adjuvant is selected from the group consisting of saponins, PCPP polymer; derivatives of lipopolysaccharides, MPL, MDP, t-MDP, OM-174 and Leishmania elongation factor.

6. The composition of claim 1, wherein the non-nucleic acid adjuvant is an adjuvant that creates a depo effect and stimulates the immune system.

7. The composition of claim 6, wherein the adjuvant that creates a depo effect

and stimulates the immune system is selected from the group consisting of ISCOMS, SB-AS2, AS2, SB-AS4, non-ionic block copolymers and SAF.

8. The composition of claim 1, wherein the composition also includes an antigen that is selected from the group consisting of peptides, polypeptides, cells, cell extracts, polysaccharides, polysaccharide conjugates, lipids, glycolipids, carbohydrates, viruses, viral extracts and antigens encoded within nucleic acids.

9. The composition of claim 8, wherein the antigen is derived from an infectious agent selected from the group consisting of a virus, bacterium, fungus and parasite.

10. The composition of claim 8, wherein the antigen is a tumor antigen.

11. The composition of claim 8, wherein the antigen is an allergen.

Previous Doc Next Doc Go to Doc#